BACKGROUND: In this study we assessed increased cortisol in Alzheimer's disease (AD) patients. The selective 11-β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor ABT-384 blocked regeneration of active cortisol and this tests the hypothesis that intracellular hypercortisolism contributes to cognitive impairment. METHODS: In this double-blind, placebo- and active-controlled phase II study we examine the efficacy and safety of ABT-384 given 10 mg or 50 mg once daily, donepezil 10 mg once daily, or placebo for 12 weeks in subjects with mild-to-moderate AD. The primary efficacy end point was the change from baseline to final evaluation on the 13-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) total score. RESULTS: The study was terminated for futility after randomization of 267 subjects. ABT-384 did not improve ADAS-Cog scores or any secondary end point; however, donepezil significantly improved both cognition and functional end points. Overall incidence of adverse events was similar among treatment groups. CONCLUSION:ABT-384, when tested at doses associated with complete brain HSD-1 inhibition, did not produce symptomatic improvement in AD.
RCT Entities:
BACKGROUND: In this study we assessed increased cortisol in Alzheimer's disease (AD) patients. The selective 11-β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor ABT-384 blocked regeneration of active cortisol and this tests the hypothesis that intracellular hypercortisolism contributes to cognitive impairment. METHODS: In this double-blind, placebo- and active-controlled phase II study we examine the efficacy and safety of ABT-384 given 10 mg or 50 mg once daily, donepezil 10 mg once daily, or placebo for 12 weeks in subjects with mild-to-moderate AD. The primary efficacy end point was the change from baseline to final evaluation on the 13-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) total score. RESULTS: The study was terminated for futility after randomization of 267 subjects. ABT-384 did not improve ADAS-Cog scores or any secondary end point; however, donepezil significantly improved both cognition and functional end points. Overall incidence of adverse events was similar among treatment groups. CONCLUSION:ABT-384, when tested at doses associated with complete brain HSD-1 inhibition, did not produce symptomatic improvement in AD.
Authors: Scott P Webster; Andrew McBride; Margaret Binnie; Karen Sooy; Jonathan R Seckl; Ruth Andrew; T David Pallin; Hazel J Hunt; Trevor R Perrior; Vincent S Ruffles; J William Ketelbey; Alan Boyd; Brian R Walker Journal: Br J Pharmacol Date: 2017-01-25 Impact factor: 8.739
Authors: Rowan S Hardy; Hannah Botfield; Keira Markey; James L Mitchell; Zerin Alimajstorovic; Connar S J Westgate; Michael Sagmeister; Rebecca J Fairclough; Ryan S Ottridge; Andreas Yiangou; Karl-Heinz H Storbeck; Angela E Taylor; Lorna C Gilligan; Wiebke Arlt; Paul M Stewart; Jeremy W Tomlinson; Susan P Mollan; Gareth G Lavery; Alexandra J Sinclair Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958
Authors: Alixe H M Kilgour; Scott Semple; Ian Marshall; Peter Andrews; Ruth Andrew; Brian R Walker Journal: J Clin Endocrinol Metab Date: 2014-11-13 Impact factor: 5.958
Authors: Karen Sooy; June Noble; Andrew McBride; Margaret Binnie; Joyce L W Yau; Jonathan R Seckl; Brian R Walker; Scott P Webster Journal: Endocrinology Date: 2015-08-25 Impact factor: 4.736
Authors: Jeffrey F Waring; Qi Tang; Weining Z Robieson; David P King; Ujjwal Das; Jordan Dubow; Sandeep Dutta; Gerard J Marek; Laura M Gault Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472